Application of Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma

Summary

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of invasive non-Hodgkin lymphoma. There is great heterogeneity in its molecular biological characteristics, clinical manifestations and prognosis. The use of rituximab has greatly improved the cure rate of DLBCL, but there are still 30% of patients with poor prognosis. In the era of precision medicine, the significance of molecular biology and genetic factors on the diagnosis, treatment and prognosis of patients has been found. Among these, next-generation sequencing technology plays an important role. This paper reviews the research progress of next-generation sequencing technology in the classification, diagnosis, prognosis and molecular targeted therapy of DLBCL.

Graphical abstract

Keywords::

• diffuse large B-cell lymphoma
• next-generation sequencing technology
• non-Hodgkin lymphoma
• precision medicine

Author contributions

Y Wang made a substantial contribution to the concept or design of the work; S Jia and X Cao acquired and interpreted the data; Y Chen and K Yu drafted the article; S Ge revised it critically for important intellectual content. All authors read and approved the final manuscript.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Data availability statement

The data used to support the findings of this study are available from the corresponding author upon request.